Ebola has left more than 1,400 people dead across West Africa, underscoring the urgency for developing potential ways to stop and treat the disease. However, health experts warn these drugs and vaccines have not undergone the rigorous testing that usually takes place before they are used.
The experimental
vaccines are at still at a Canadian laboratory, said Patrick Gaebel, spokesman
for the Public Health Agency of Canada, who declined to speculate how many
weeks it could be before those are given to volunteers.
"We are now working
with the (World Health Organization) to address complex regulatory, logistical
and ethical issues so that the vaccine can be safely and ethically deployed as
rapidly as possible," Gaebel said.
Earlier this month,
Canada said it would donate 800 to 1,000 doses of an Ebola vaccine that it
developed. Likely candidates include health care workers treating Ebola
patients.
The experimental drug
known as ZMapp has been tried in only six people. Health experts caution that
since ZMapp was never tested in humans, it is unclear whether it works. The
small supply is now said to be exhausted and it is expected to be months before
more can be produced.
Dr. Abraham Borbor, the
deputy chief medical doctor at Liberia's largest hospital, had received ZMapp,
along with two other Liberians. He "was showing signs of improvement but
yesterday he took a turn for the worse," and died Sunday, Information
Minister Lewis Brown told The Associated Press.
There was no update
provided Monday on the other two Liberians who received the drug.
Earlier, it had been
given to two Americans aid workers and a Spanish missionary priest, who died
after he left Liberia. After receiving rigorous medical care in the U.S., the
Americans survived the virus that has killed about half of its victims.
Ebola can cause a grisly
death with bleeding from the eyes, mouth and ears. The virus can only be
transmitted through direct contact with the bodily fluids of the sick or from
touching victims' bodies, leaving doctors and other health care workers most
vulnerable to contracting it.
International relief
efforts have included shipments of gloves, gowns, face masks and other
protective equipment, although it's not clear how many have reached health
workers struggling to contain the epidemic in West Africa, where even such
basics as sterile fluids can be in short supply.
But just getting enough
gear isn't the whole story: Health workers can infect themselves while taking
off contaminated equipment if they don't do it properly, a trio of infectious
disease experts wrote Monday in Annals of Internal Medicine.
"The physical
exhaustion and emotional fatigue that come with caring for patients infected
with Ebola may further increase the chance of an inadvertent exposure to bodily
fluids on the outside of the" personal protective equipment, wrote Dr.
William A. Fisher II of the University of North Carolina, Chapel Hill, along
with Drs. Trish Perl and Noreen Hynes of Johns Hopkins University.
"In addition, the
impulse to wipe away sweat in the ever-present hot, humid environment"
after taking off some gear, and before washing up, could be enough, they added.
Meanwhile, the family of
29-year-old William Pooley, the first British citizen confirmed to be infected
with Ebola, said he is receiving excellent care at an isolation ward in
London's Royal Free Hospital after being evacuated from the capital of Sierra
Leone.
"We could not ask
for him to be in a better place," they said in a statement.
Pooley, a volunteer
nurse, was flown back to Britain from Sierra Leone where he was working at an
Ebola treatment centerThe WHO is also in the process of trying to evacuate a Senegalese doctor who contracted Ebola while working in Sierra Leone, said WHO Assistant Director General, Dr. Keiji Fukada on Monday.
The U.N. on Monday also spoke out against the limitations placed on flights into and out of the affected countries, saying they are slowing aid organizations' work in sending personnel and equipment and contributing to the countries' "economic and diplomatic isolation."
"We shouldn't do anything that stokes fear and stigmatization," Stephane Dujarric, spokesman for the U.N. secretary-general, told reporters.
On Monday, Japan also said it is ready to provide a newly developed anti-influenza drug as a possible treatment Ebola. The drug, with the brand name Avigan, was developed by Fujifilm subsidiary Toyama Chemical Co. to treat new and re-emerging influenza viruses, and has not been proven to be effective against Ebola.
Source: YAHOO NEWS


No comments:
Post a Comment